Priority Review for Novartis' Tafinlar plus Mekinist for melanoma

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA accepted and granted Priority Review to an sNDA for Tafinlar

Read the full 161 word article

User Sign In